Search Result

Results for "

mitochondrial myopathy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calcineurin (1) Endogenous Metabolite (5) Farnesyl Transferase (1) HMG-CoA Reductase (HMGCR) (1) Isotope-Labeled Compounds (3) PPAR (2) Ras (1) Reference Standards (1)
By Research Areas:	Cancer (1) Inflammation/Immunology (8) Metabolic Disease (8)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Mitochondrial Metabolism Mitophagy

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107855

DL-Mevalonolactone 1 Publications Verification (±)-Mevalonolactone; Mevalolactone	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

HY-134377

Bocidelpar ASP0367; MA-0211	PPAR	Metabolic Disease
Bocidelpar (ASP0367; MA-0211) is a selective, orally active PPARδ modulator. Bocidelpar activates the PPARδ downstream signaling pathway, upregulates the expression of target genes such as ABCA1 and ACAA2. Bocidelpar then promotes fatty acid oxidation (FAO) and mitochondrial biogenesis, and improves mitochondrial dysfunction. Bocidelpar can improve mitochondrial biogenesis and function in muscle cells. Bocidelpar is mainly used in the study of mitochondrial dysfunction diseases such as primary mitochondrial myopathy (PMM) and Duchenne muscular dystrophy (DMD) .

HY-112597A

Mavodelpar REN001; HPP593	PPAR	Inflammation/Immunology
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD) . Mavodelpar is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135700

Mevalonolactone	Calcineurin Ras HMG-CoA Reductase (HMGCR)	Metabolic Disease Inflammation/Immunology
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-107855R

DL-Mevalonolactone (Standard) (±)-Mevalonolactone (Standard); Mevalolactone (Standard)	Endogenous Metabolite Reference Standards	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone (Standard) is the analytical standard of DL-Mevalonolactone. This product is intended for research and analytical applications. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

HY-106431

Olpadronic acid Olpadronate; OLP	Farnesyl Transferase	Metabolic Disease Inflammation/Immunology Cancer
Olpadronic acid (Olpadronate) is an orally active amino-bisphosphonate and inhibits bone resorption. Olpadronic acid prevents bone destruction and tumor growth in the skeletal prostate cancer mouse model. Olpadronic acid can be used for research of osteoporosis, malignancies and rheumatoid arthritis .

HY-107855S2

DL-Mevalonolactone-13C (±)-Mevalonolactone-¹³C; Mevalolactone-¹³C	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone- ¹³C ((±)-Mevalonolactone- ¹³C) is the ¹³C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.

HY-107855S4

DL-Mevalonolactone-13C2 (±)-Mevalonolactone-¹³C₂; Mevalolactone-¹³C₂	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone- ¹³C₂ ((±)-Mevalonolactone- ¹³C₂) is the ¹³C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

HY-W752587

DL-Mevalonolactone-d4 (±)-Mevalonolactone-d₄; Mevalolactone-d₄	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone-d₄ ( (±)-Mevalonolactone-d₄) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107855

DL-Mevalonolactone 1 Publications Verification (±)-Mevalonolactone; Mevalolactone	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite
DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

HY-135700

Mevalonolactone	Structural Classification Microorganisms Other Phenylpropanoids Phenylpropanoids Source Classification	Calcineurin Ras HMG-CoA Reductase (HMGCR)
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-107855R

DL-Mevalonolactone (Standard) (±)-Mevalonolactone (Standard); Mevalolactone (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
DL-Mevalonolactone (Standard) is the analytical standard of DL-Mevalonolactone. This product is intended for research and analytical applications. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

Cat. No.	Product Name	Chemical Structure

HY-107855S2

DL-Mevalonolactone-13C
DL-Mevalonolactone- ¹³C ((±)-Mevalonolactone- ¹³C) is the ¹³C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.

DL-Mevalonolactone-13C

DL-Mevalonolactone- ¹³C ((±)-Mevalonolactone- ¹³C) is the ¹³C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.

HY-107855S4

DL-Mevalonolactone-13C2
DL-Mevalonolactone- ¹³C₂ ((±)-Mevalonolactone- ¹³C₂) is the ¹³C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

DL-Mevalonolactone-13C2

DL-Mevalonolactone- ¹³C₂ ((±)-Mevalonolactone- ¹³C₂) is the ¹³C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

HY-W752587

DL-Mevalonolactone-d4
DL-Mevalonolactone-d₄ ( (±)-Mevalonolactone-d₄) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

DL-Mevalonolactone-d4

DL-Mevalonolactone-d₄ ( (±)-Mevalonolactone-d₄) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks